AVE Chimera is advancing the industrial development and commercialization of XYLIUM and complementary specialty-material technologies in North America.
The current business plan describes an initial U.S. financing round intended to fund laboratory and production equipment, technology transfer and startup costs, followed by a later scale-up round.
REQUEST INVESTOR INFORMATION →Financing terms remain subject to definitive capitalization, securities, licensing and offering documentation. This website is informational and is not an offer to sell securities.
